BioCardia
BCDA
23 hedge funds and large institutions have $3.17M invested in BioCardia in 2022 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 4 closing their positions.
219% more call options, than puts
Call options by funds: $571K | Put options by funds: $179K
133% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 3
2% more capital invested
Capital invested by funds: $3.1M → $3.17M (+$68K)
0.2% less ownership
Funds ownership: 0.82% → 0.61% (-0.2%)
12% less funds holding
Funds holding: 26 → 23 (-3)
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FM
Family Management
New York
|
+$245K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$49K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
+$36.2K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
+$6.1K |
| 5 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$5.17K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
-$958K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$30.5K |
| 3 |
Cetera Investment Advisers
Schaumburg,
Illinois
|
-$18K |
| 4 |
Millennium Management
New York
|
-$11.7K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$5.51K |
BCDA Hedge Fund Activity: Q3 2022 in Review
23 of the 5,827 institutional investors tracked by Wall St. Rank reported a position in BioCardia (BCDA) for Q3 2022, worth a combined $3.17M — up 2.2% from $3.1M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of BCDA and 1 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 7 added.
The largest buyer was Family Management, opening a new position worth an estimated $245K. The largest seller was CAPTRUST Financial Advisors, exiting entirely with an estimated $958K sold.
- 23 institutional investors held BioCardia (BCDA) as of Q3 2022, down from 26 in Q2 2022.
- Funds reported $3.17M of BioCardia stock for Q3 2022, up 2.2% quarter-over-quarter.
- 1 fund opened new BioCardia positions in Q3 2022 and 4 closed out, a net change of -3 holders.
- The largest BioCardia buyer in Q3 2022 was Family Management, an estimated $245K added.
- The largest BioCardia seller in Q3 2022 was CAPTRUST Financial Advisors, an estimated $958K sold.
Based on aggregated 13F filings for Q3 2022.